Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Niraparib showed promising activity in preclinical models and phase I clinical trials, achieving its pharmacodynamic target for PARP inhibition in epithelial ovarian cancer, particularly in patients who have responded to platinum-based chemotherapy 167 (Fig
: : _ :
So next time you hear someone blame their rising health premiums on the new GLP-1 pill, you might share this bigger picture: yes, that new pill is part of the cost puzzle, but so are a lot of other expensive pieces that have been on the board for years
Testimonials I didn't wait long
However, their cytotoxicity limited their application in nanoparticle design
US$ 23.07
US$ 21.89
US$ 22.60
US$ 28.65
